BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Voss N, Izbicki JR, Nentwich MF. Oligometastases in pancreatic cancer (Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis). Ann Gastroenterol Surg 2019;3:373-7. [PMID: 31346576 DOI: 10.1002/ags3.12255] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Sahores A, Carozzo A, May M, Gómez N, Di Siervi N, De Sousa Serro M, Yaneff A, Rodríguez-González A, Abba M, Shayo C, Davio C. Multidrug transporter MRP4/ABCC4 as a key determinant of pancreatic cancer aggressiveness. Sci Rep 2020;10:14217. [PMID: 32848164 DOI: 10.1038/s41598-020-71181-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Tsutsumi C, Abe T, Shinkawa T, Nishihara K, Tamiya S, Nakano T. Long-term survival after hepatectomy for metachronous liver metastasis of pancreatic ductal adenocarcinoma: a case report. Surg Case Rep 2020;6:157. [PMID: 32621095 DOI: 10.1186/s40792-020-00924-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Imai K, Margonis GA, Wang J, Wolfgang CL, Baba H, Weiss MJ. Liver metastases from pancreatic ductal adenocarcinoma: is there a place for surgery in the modern era? Journal of Pancreatology 2020;3:81-5. [DOI: 10.1097/jp9.0000000000000042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Das S, Berlin J. Systemic Therapy Improvements Will Render Locoregional Treatments Obsolete for Patients with Cancer with Liver Metastases. Surg Oncol Clin N Am 2021;30:189-204. [PMID: 33220805 DOI: 10.1016/j.soc.2020.08.008] [Reference Citation Analysis]
5 Wei M, Shi S, Hua J, Xu J, Yu X; Chinese Study Group for Pancreatic Cancer (CSPAC). Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1). BMJ Open 2019;9:e033452. [PMID: 31818843 DOI: 10.1136/bmjopen-2019-033452] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Armutlu A, Saeed O, Saxena R. Metastatic Liver Tumors in Surgical Pathology: Impact of Contemporary Diagnostic and Therapeutic Paradigms in a Tertiary Care Center. Int J Surg Pathol 2021;:10668969211022708. [PMID: 34125627 DOI: 10.1177/10668969211022708] [Reference Citation Analysis]
7 Nie D, Lai G, An G, Wu Z, Lei S, Li J, Cao J. Individualized Prediction of Survival Benefits of Pancreatectomy Plus Chemotherapy in Patients With Simultaneous Metastatic Pancreatic Cancer. Front Oncol 2021;11:719253. [PMID: 34604055 DOI: 10.3389/fonc.2021.719253] [Reference Citation Analysis]